Is 6M TCZ treatment enough to induce lasting remission in PMR? ➡️cohort of pts in SEMAPHORE trial ➡️among pts in remission after 6M TCZ, 1/4 were relapse-free after TCZ discontinuation ⏩6M treatment not enough to withdraw TCZ Ab1698 #ACR24 @RheumNow https://t.co/wTRTfX1fWq

Is #IL1 inhibition for 4 months a winner in #GCA —NOPE Anakinra daily 100mg sc 4/12 Underpowered but equal relapses and d/c #steroids not different #relapses esp after d/c #anakinra N=30 d/c due to #COVIDpandemic #1699 #ACR24 @RheumNow @ACRheum https://t.co/1TgloS5x8O

A#1693 Change in FVC @ W12 or 24 has progn value @ w52 in AI-ILD Study SENSCIS (SSc) & INBUILD (SARD) trial PBO gps SENSCIS: OR for ILD progression 1.9 @ w12, 2.5 @ w24 INBUILD: OR 2.2 @ w12 & w24 Early PFTs predict outcomes @ 1 yr, short trials may be feasible #ACR24 @RheumNow https://t.co/8cICAeG0nr

How do you manage skin in Sscl? -RNA pol III + high risk for skin progression. -Limited+ low risk + stable Sscl no need for immunesuppresors. -Look for EF in pts with generalized morphea. -Ttnt of skin depending on other organ involvements. -If no Raynaud’s/hands spared think of… https://t.co/HBjO5eQfjT https://t.co/oS1ZmkanGA

de Boysson et al. RCT anakinra in GCA. 30 patients. Week 52 relapse 53% in anakinra vs 46% in placebo. @RheumNow #ACR24 Abstr#1699 https://t.co/sqDWUlkXAX

Sarilumab is better than #MTX in #PMR Reminder #RCT of #MTX in #PMR was a NEGATIVE #trial #1697 60 % #sarilumab in #RWE could d/c #Prednisone after failure of initial #pred #Rx >1yr pred prior vs 40% MTX Comparative effectiveness sari v MTX #1700 #ACR24 @ACRheum @RheumNow https://t.co/4YXIBz0OK7

A retrospective analysis by Dr. ERayens et al showed that RA pts >/=50y given 2 RZV doses were less likely to develop HZ vs. unvaxxed grp Incidence of PHN was also lower in the vaccinated group (0.2py vs.1.9py) RZV is effective in preventing HZ & PhN @Rheumnow #ACR25 abs0977 https://t.co/JhYBYnLmhl